Failure in Longterm Treatment is Rare in Actively Treated Patients with Rheumatoid Arthritis, But May Be Predicted by High Health Assessment Score at Baseline and by Residual Disease Activity at 3 and 6 Months: The 5-year Followup Results of the Randomized Clinical NEO-RACo Trial
Authors:
- Vappu RantalaihoVRVappu Rantalaiho
- Hannu KautiainenHKHannu Kautiainen
- Salme JärvenpääSJSalme Järvenpää
- Markku KorpelaMKMarkku Korpela
- Timo MalmiTMTimo Malmi
- Pekka HannonenPHPekka Hannonen
- Oili Kaipiainen-SeppänenOKOili Kaipiainen-Seppänen
- Timo Yli-KerttulaTYTimo Yli-Kerttula
- Timo MöttönenTMTimo Möttönen
- Anu MustilaAMAnu Mustila
- Anna KarjalainenAKAnna Karjalainen
- Leena PaimelaLPLeena Paimela
- 1 October 2014
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 41 (12) , 2379-2385
Abstract
Objective.: With modern initial aggressive combination treatments with synthetic disease-modifying antirheumatic drugs (sDMARD), most patients with rheumatoid arthritis (RA) achieve remission, have marginal radiographic progression, and sustain normal function. Here we aim to identify the patients failing these targets even after aggressive treatment.Methods.: Ninety-nine patients with early, active RA were treated with a combination of 3 sDMARD and prednisolone (PRD), and either infliximab or placebo infusions during the first 6 months, aiming at strict remission. After 24 months, the treatments became unrestricted. At 60 months, 4 evident clinical features of treatment failure were defined: area under curve (AUC) between 6–60 months for disease activity score assessing 28 joints > 2.6; AUC 6–60 for health assessment questionnaire > 0.5; progression in total Sharp/van der Heijde score 0–60 months > 3 units; and need of PRD or biologic DMARD treatment at 60 months.Results.: A total of 93 patients were followed up for 60 months. Of them, 45 had no features of treatment failure, 30 had 1, 10 had 2, 7 had 3, and 1 patient had all 4 features. Having 2–4 features of treatment failure at 5 years was predicted by the health assessment score at baseline, and by even low residual disease activity at 3 and 6 months.Conclusions.: Only 20% of the patients with RA treated early with combination sDMARD and PRD have more than 1 clinical feature of treatment failure at 60 months. Residual clinical disease activity at 3–6 months was the most important predictor for identifying these patients. The study was registered at www.clintrials.gov (NCT00908089).Keywords
This publication has 24 references indexed in Scilit:
- Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)Annals of the Rheumatic Diseases, 2013
- Metabolic Profiling Predicts Response to Anti–Tumor Necrosis Factor α Therapy in Patients With Rheumatoid ArthritisArthritis & Rheumatism, 2013
- In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trialAnnals of the Rheumatic Diseases, 2012
- Treating rheumatoid arthritis to target: recommendations of an international task forceAnnals of the Rheumatic Diseases, 2010
- Assessing adequate treatment response in patients with rheumatoid arthritisClinical Therapeutics, 2009
- Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis?Annals of the Rheumatic Diseases, 2009
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trialsArthritis & Rheumatism, 1993
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980